All Stories

VC Longwood Fund unveils neuro biotech with $93M, assets licensed from Roche

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments, plus several clinical programs from Roche in hand.

Feb 13, 2025 - 09:38
 0
VC Longwood Fund unveils neuro biotech with $93M, assets licensed from Roche
Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments, plus several clinical programs from Roche in hand.
Read More

Tags:

Previous Article

Growth Advisors International Network (GAIN) Announces Asia Pacific Leadership Team

Next Article

New product information wording – Extracts from PRAC recommendations on signals ...

Related Posts

BioCity’s ETA antagonist reduces proteinuria in phase 2 trial of diabetic kidney disease

BioCity’s ETA antagonist reduces proteinuria in phase 2...

Feb 25, 2025  0

Cullinan CEO talks autoimmune pivot, upcoming lupus readout and his 'thriller or killer' approach

Cullinan CEO talks autoimmune pivot, upcoming lupus rea...

Feb 9, 2025  0

Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial

Australian biotech points to potential superbug use as ...

Feb 19, 2025  0